The stock of Cardiff Oncology Inc (CRDF) has gone up by 5.44% for the week, with a -18.21% drop in the past month and a -12.43% drop in the past quarter. The volatility ratio for the week is 7.21%, and the volatility levels for the past 30 days are 7.99% for CRDF. The simple moving average for the past 20 days is 6.60% for CRDF’s stock, with a -0.74% simple moving average for the past 200 days.
Is It Worth Investing in Cardiff Oncology Inc (NASDAQ: CRDF) Right Now?
The stock has a 36-month beta value of 1.76. Opinions on the stock are mixed, with 5 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for CRDF is 59.79M, and at present, short sellers hold a 24.77% of that float. On April 23, 2025, the average trading volume of CRDF was 1.22M shares.
CRDF) stock’s latest price update
Cardiff Oncology Inc (NASDAQ: CRDF) has experienced a rise in its stock price by 1.64 compared to its previous closing price of 3.05. However, the company has seen a gain of 5.44% in its stock price over the last five trading days. globenewswire.com reported 2025-04-15 that SAN DIEGO, April 15, 2025 (GLOBE NEWSWIRE) — Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that on April 14, 2025, non-qualified stock option awards to purchase an aggregate of 35,040 shares of its common stock were granted to one new employee. The stock options were granted as inducements material to the new employee becoming an employee of Cardiff Oncology in accordance with Nasdaq Listing Rule 5635(c)(4).
Analysts’ Opinion of CRDF
Many brokerage firms have already submitted their reports for CRDF stocks, with Craig Hallum repeating the rating for CRDF by listing it as a “Buy.” The predicted price for CRDF in the upcoming period, according to Craig Hallum is $8 based on the research report published on September 06, 2024 of the previous year 2024.
Robert W. Baird gave a rating of “Outperform” to CRDF, setting the target price at $19 in the report published on December 08th of the previous year.
CRDF Trading at -14.35% from the 50-Day Moving Average
After a stumble in the market that brought CRDF to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -45.03% of loss for the given period.
Volatility was left at 7.99%, however, over the last 30 days, the volatility rate increased by 7.21%, as shares sank -17.89% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -31.88% lower at present.
During the last 5 trading sessions, CRDF rose by +6.12%, which changed the moving average for the period of 200-days by +41.18% in comparison to the 20-day moving average, which settled at $2.91. In addition, Cardiff Oncology Inc saw -28.57% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CRDF starting from Levine James E., who purchase 2,752 shares at the price of $5.42 back on Dec 17 ’24. After this action, Levine James E. now owns 65,316 shares of Cardiff Oncology Inc, valued at $14,905 using the latest closing price.
Levine James E., the Chief Financial Officer of Cardiff Oncology Inc, purchase 2,400 shares at $5.00 during a trade that took place back on Dec 18 ’24, which means that Levine James E. is holding 67,716 shares at $12,000 based on the most recent closing price.
Stock Fundamentals for CRDF
Current profitability levels for the company are sitting at:
- -71.13 for the present operating margin
- 0.7 for the gross margin
The net margin for Cardiff Oncology Inc stands at -66.42. The total capital return value is set at -0.58. Equity return is now at value -59.51, with -50.81 for asset returns.
Based on Cardiff Oncology Inc (CRDF), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at -24.75.
Currently, EBITDA for the company is -48.65 million with net debt to EBITDA at 1.04. When we switch over and look at the enterprise to sales, we see a ratio of 222.16. The receivables turnover for the company is 0.88for trailing twelve months and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.08.
Conclusion
To sum up, Cardiff Oncology Inc (CRDF) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
